

GNYHA NYC ED MAT Quality Collaborative Assessment

As part of the New York City Emergency Department (ED) Medication-Assisted Treatment (MAT) Quality Collaborative, GNYHA requests that staff from your hospital complete this assessment to help establish a baseline for current hospital practices as well as inform future collaborative programming. Please coordinate with staff across your ED and hospital to answer the assessment questions at the individual hospital level. GNYHA requests your hospital complete and submit the assessment through the following link, https://www.surveymonkey.com/r/NYCEDMAT, by Friday, <a href="https://www.surveymonkey.com/r/NYCEDMAT, by Friday, November 6.

If you have any questions regarding the assessment, please contact <u>Jared Bosk</u> and <u>Courtney Zyla</u>.

Contact Information

Please enter the following:		
Name:	 	
Title:		
Email:		
Phone:		
Q0 Please enter your hospital:		



Section 1: ED Capacity to Prescribe Buprenorphine

Section 1. LD	capacity to Frescrib	e bupi enoi pini	iie			
Q1 Does your waivered?	Emergency Departm	nent (ED) currer	ntly have any prescri	bers who are DAT	A-2000	
O Yes						
O No						
O Not	sure					
[IF NO OR NOT	SURE, SKIP TO Q1.2	2]				
Q1.1 Please se and by phone.	•	esents your hos	pital's waivered pres	scribers' availabili	ty both in-persor	
		Few shifts	Some shifts	Most shifts	All shifts	
	In person					
	By phone					
Q1.2 Has your select all that a	•	following to inc	crease the number o	f waivered prescr	ibers? Please	
□ Crea	ited a campaign in y	our ED to enco	urage prescribers to	get waivered		
□ Trac	ked and monitored	number of waiv	vered ED prescribers			
□ Held	☐ Held a waiver training onsite					
$\hfill\Box$ Coordinated an offsite waiver training that your prescribers could attend						
$\hfill\Box$ Provided info to your prescribers on how they could complete waiver training independently						
$\hfill\Box$ Compensated prescribers for the time it took to complete their waiver training						
□ Othe	□ Other, please specify:					
□ My I	$\hfill \square$ My ED has not done anything to increase the number of waivered prescribers					



Section Two: Identifying Patients for Buprenorphine Induction in the ED

Q2 What best describes how your ED screens patients for Substance Use Disorders (SUD)?
O We use a standardized screening tool (e.g., ASSIST, AUDIT, DAST)
O We use a homegrown screening tool
O We do not screen for SUD
O Other, please specify:
[IF "We do not screen for SUD," SKIP TO Q2.3]
Q2.1 What best describes the screening tools your ED uses?
O Screening tools ask specifically about opioids
O Screening tools ask about some specific substances, but not opioids specifically
O Screening tools only ask about substance use generally
O Other, please specify:
Q2.2 What best describes your ED's process for screening patients for an SUD?
O All patients are screened
O Patients are screened when staff is available for screening
O Patients are screened only when there is a suspicion they may have an SUD
O Other, please specify:
Q2.3 How does your ED identify patients with potential Opioid Use Disorders (OUD)? Please select al that apply.
☐ Conduct formal screening
☐ Initiate informal conversation about opioid use
□ Receive practitioner/Community referral
☐ Review Prescription Drug Monitoring Program (PDMP) database
☐ Review PSYCKES for previous OUD flags
□ Review PSYCKES for case history
□ Other, please specify:
☐ My ED does not have a process to identify patients with OUD



Please select all that apply.

All patients

Patients in withdrawal

Patients who express interest

Other, please specify:

Buprenorphine is not discussed with patients

Q2.5 Does your ED provide any harm reduction strategies to patients with OUD? Please select all that apply.

Providing opioid overdose prevention education to patients with OUD and patients at risk of opioid overdose

Discharging patients with a high-risk of opioid overdose with a naloxone kit

Discharging patients with a high-risk of opioid overdose with a naloxone prescription or referral to an overdose prevention program

Discharging patients with a referral to a syringe access program

□ Our ED does not provide any harm reduction strategies to patients with OUD

□ Other, please specify: _____

Q2.4 For patients identified as having OUD, with which subset(s) does your ED discuss buprenorphine?



Section 3: Increasing Provision of Buprenorphine in the ED

Q3 Is buprenorphine on your hospital's formulary?	
O Yes	
O No	
Q3.1 Does your ED have a protocol in place to provide patients with OUD with buprenorphine?	
O Yes	
O No	
[IF NO, SKIP TO Q4]	
Q3.2 Who has been trained on the buprenorphine protocol? Please select all that apply.	
□ All prescribers	
□ Prescribers with their DATA-2000 waiver only	
□ Nurses	
□ Social workers	
□ Clerks	
☐ Discharge planners	
□ Other, please specify:	
$\hfill\Box$ There has been no training on the buprenorphine protocol	
Q3.3 Which of the following are included in your ED's buprenorphine protocol? Please select all that apply.	
☐ Induction in the ED for patients who are eligible	
$\hfill\Box$ Ability for interested patient to spend time in observation until they are eligible for inducti	or
☐ Process to prescribe buprenorphine to patients for home induction	
$\hfill\Box$ Provision of buprenorphine "home pack" to allow for home induction	
$\hfill\Box$ Process to prescribe buprenorphine to patients who were induced in the ED	
$\hfill\Box$ Process to induce patients who came into the ED because of an opioid overdose or overdo reversal	se
□ Other, please specify:	
□ None of the above	



Q3.4 Ho	ow does ED staff access your ED's buprenorphine protocol? Please select all that apply.
	☐ The protocol is available within our EMR
	□ Protocol pocket guides
	☐ The protocol is available at ED stations
	□ Other, please specify:
Q3.5 W	hat best describes how your ED determines if a patient is eligible for buprenorphine induction?
	O Complete the COWS and use formal cutoff score
	O Complete the COWS but also have conversation with patient to determine if they are in withdrawal
	O Have conversation with patient to determine if they are in withdrawal
	O Other, please specify:
[IF COW	VS IS NOT USED, SKIP TO Q3.7]
Q3.6 Ple	ease type in the minimum COWS score required to make a patient eligible for buprenorphine on.
	II
Q3.7 Ho	ow are patients made aware of your ED's ability to provide buprenorphine? Please select all that
	☐ Signs in the waiting area and rooms mention availability of buprenorphine
	$\hfill \square$ Signs in the waiting area and rooms encourage patients to discuss treatment options for opioid use
	$\hfill\Box$ Pamphlets provided to patients to make them aware of buprenorphine availability
	$\hfill\Box$ Information provided (formal and informal) to community-based providers
	□ Other, please specify:
	□ ED does not proactively make patients aware of availability of buprenorphine



Q3.8 Which of the following additional staffing resources are available in your ED to work with patients with OUD? Please select all that apply.

□ Certified Recovery Peer Advocate (CRPA)
$\hfill \Box$ Credentialed Alcohol and Substance Abuse Counselor (CASAC)/Recovery Coaches
□ Social Workers
□ Care Coordinators/Care Navigators
□ Mental Health Counselors
□ Addiction Medicine Specialist Consult
□ Other, please specify:
☐ My FD does not have any of these additional staffing resources



Section 4: Improving Connections with Community OUD Providers

Q4 How frequently do the following occur for patients seen in your ED who have been identified as having OUD?

	Always	Most of	Sometimes	Rarely	Never
		the time			
Patient is discharged with appointment					
scheduled with community provider					
Discharge planners have discussion with					
patient about different referral options					
Discharge planners hand out written list of					
referral options					
Patients are seen by a community provider					
within a day or two of their discharge					
Community providers provide information back					
to ED on whether patient has shown up to					
appointment					
Community providers provide information back					
to ED on whether patient remains in treatment					

Q4.1 Does your hospital have a preferred list of community SUD providers?
O Yes
O No
[IF NO, SKIP TO Q5]
Q4.2 How do you evaluate these community SUD providers? Please select all that apply.
□ Scheduling availability
□ Hours of operation
☐ Availability of needed services
□ Proximity to hospital
□ Shared prescribers
□ Quality measures
□ Other, please specify:
☐ Our hospital does not evaluate our community SUD providers



Section 5: Training and Data

Q5 In t	the last 12 months, has your ED conducted any training on Substance Use Disorder?
	O Yes
	O No
[IF NO	TRAINING, SKIP TO Q5.4]
Q5.1 V	Which of the following staff types received training on SUD? Please select all that apply.
	□ All prescribers
	□ Prescribers with their DATA-2000 waiver only
	□ Nurses
	□ Social workers
	□ Clerks
	☐ Discharge planners
	□ Other, please specify:
Q5.2 V	What topics were included in the training? Please select all that apply.
	☐ Information on different types of Substance Use Disorder
	☐ Focus specifically on Opioid Use Disorder
	☐ Information on Medications for Addiction Treatment
	☐ Stigma and stigmatizing language
	☐ Data on prevalence of Substance Use Disorders
	☐ Data on mortality associated with Substance Use Disorders
	☐ Information on cycle and course of Substance Use Disorders
	□ Other, please specify:
Q5.3 V	Vho conducted the training?
	O Hospital staff
	O Public health department
	O Community provider
	O Outside training group
	O Other, please specify:



Q5.4 Does your hospital currently collect data related to OUD?
O Yes
O No
O Not sure
[IF NO, SKIP TO Q6]
Q5.5 What type of data do you collect? Please select all that apply.
□ Screenings
□ Protocols Initiated
□ ED Inductions
☐ Home Inductions
□ Community Referrals
□ Other, please specify:
Q5.6 Is this data shared with ED front-line staff?
O Yes
O No
O Not sure
Q5.7 Do your community clinics share referred patients' data with you?
O Yes
O No
O Not sure
[IF NO OR NOT SURE, SKIP TO Q6]
Q5.8 What type of data do the clinics share? Please select all that apply.
□ Appointments filled
□ MAT refills
☐ Follow-up appointments filled
□ Success stories
□ Other, please specify:
[IF SUCCESS STORIES ARE NOT SHARED, SKIP TO Q6]



Q5.9 Are these community clinic success stories shared with ED staff?

- O Yes
- O No
- O Not sure



Section 6: Barriers and Challenges to Providing Buprenorphine in the ED

Q6 Please rank the following barriers from most challenging to least challenging regarding their impact on providing buprenorphine in your ED. $(1 = most challenging, 6 = least challenging)$
Prescriber buy-in
Lack of waivered prescribers
Identifying eligible OUD patients
Stigma surrounding opioid addiction
Time and resources to complete induction in ED
Availability of community OUD providers to refer patients to
Q6.1 Has your ED identified any of the following champions to lead prescribing buprenorphine in your ED to patients with OUD? Please select all that apply.
□ Executive champion
□ Clinical champion
☐ Front-line staff champion
□ Peer champion
□ Community partner champion
Q6.2 Please provide any additional information that you think GNYHA should have to best support your hospital with your ED MAT efforts.